Last reviewed · How we verify
NCT06058988
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Recruiting now
Phase 2
Last updated 23 February 2026
What this trial tests
Phase 2 trial testing Trastuzumab deruxtecan in Brain Cancer in 30 participants. Currently enrolling.
Timeline
22 September 2023
Primary endpoint
22 September 2027
22 September 2027
22 September 2027
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 22 September 2023 |
| Primary completion | 22 September 2027 |
| Estimated completion | 22 September 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Trastuzumab deruxtecan — full drug profile →
Conditions studied
- Brain Cancer — all drugs for Brain Cancer →
- Glioblastoma — all drugs for Glioblastoma →
- Metastatic Cancer — all drugs for Metastatic Cancer →
- Leptomeningeal Metastasis — all drugs for Leptomeningeal Metastasis →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
18 and older, any sex, with Brain Cancer or Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
A brave new framework for glioma drug development.
Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, et al · · 2024 · cited 23× · PMID 39362262 · DOI 10.1016/s1470-2045(24)00190-6 -
The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology.
van Opijnen MP, de Vos FYF, Cuppen E, Geurts M, et al · · 2024 · cited 2× · PMID 39316248 · DOI 10.1007/s12032-024-02501-7 -
Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases.
Anders CK, Van Swearingen AED, Neman J, Joyce JA, et al · · 2025 · cited 1× · PMID 40276376 · DOI 10.1093/noajnl/vdaf049 -
Monoclonal Antibodies-Anchored Quantum Dots-Based Delivery Strategies for Glioblastoma Treatment: Challenges and Applications.
Bari DB, Pardeshi CV. · · 2025 · PMID 40922752 · DOI 10.34172/apb.025.44026 -
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges.
Robert SM, Toth A, Lev S, Bowden SG, et al · · 2025 · PMID 40471420 · DOI 10.1007/s11060-025-05083-0
Verify or expand the search:
- PubMed search for NCT06058988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Trastuzumab deruxtecan
Trials testing the same drug.
- NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07086768 — Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metast · Phase 1 · not yet recruiting
- NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
- NCT07060807 — A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) · Phase 3 · recruiting
- NCT06989112 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Tre · Phase 3 · recruiting
Other recruiting trials for Brain Cancer
Currently open trials in the same condition.
- NCT07374692 — Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors · NA · recruiting
- NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting
- NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
- NCT05943262 — Record Voxel Rate Nonlinear Optical Microscope to Unravel Brain Connectome and Signaling · recruiting
- NCT05947149 — HRQoL in Patients With Solid Tumors Treated With Hadrontherapy · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06058988 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 23 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06058988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing